One Full or Two Fractional Doses of Inactivated Poliovirus Vaccine for Catch-up Vaccination in Older Infants: A Randomized Clinical Trial in Bangladesh
- PMID: 35575051
- PMCID: PMC9574668
- DOI: 10.1093/infdis/jiac205
One Full or Two Fractional Doses of Inactivated Poliovirus Vaccine for Catch-up Vaccination in Older Infants: A Randomized Clinical Trial in Bangladesh
Abstract
Background: The polio eradication endgame called for the removal of trivalent oral poliovirus vaccine (OPV) and introduction of bivalent (types 1 and 3) OPV and inactivated poliovirus vaccine (IPV). However, supply shortages have delayed IPV administration to tens of millions of infants, and immunogenicity data are currently lacking to guide catch-up vaccination policies.
Methods: We conducted an open-label randomized clinical trial assessing 2 interventions, full or fractional-dose IPV (fIPV, one-fifth of IPV), administered at age 9-13 months with a second dose given 2 months later. Serum was collected at days 0, 60, 67, and 90 to assess seroconversion, priming, and antibody titer. None received IPV or poliovirus type 2-containing vaccines before enrolment.
Results: A single fIPV dose at age 9-13 months yielded 75% (95% confidence interval [CI], 6%-82%) seroconversion against type 2, whereas 2 fIPV doses resulted in 100% seroconversion compared with 94% (95% CI, 89%-97%) after a single full dose (P < .001). Two doses of IPV resulted in 100% seroconversion.
Conclusions: Our study confirmed increased IPV immunogenicity when administered at an older age, likely due to reduced interference from maternally derived antibodies. Either 1 full dose of IPV or 2 doses of fIPV could be used to vaccinate missed cohorts, 2 fIPV doses being antigen sparing and more immunogenic.
Clinical trial registration: NCT03890497.
Keywords: Bangladesh; fractional IPV; inactivated poliovirus vaccine; older cohort; polio.
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Conflict of interest statement
Potential conflicts of interest . All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Figures
Similar articles
-
Immunogenicity to poliovirus type 2 following two doses of fractional intradermal inactivated poliovirus vaccine: A novel dose sparing immunization schedule.Vaccine. 2017 May 19;35(22):2993-2998. doi: 10.1016/j.vaccine.2017.03.008. Epub 2017 Apr 20. Vaccine. 2017. PMID: 28434691 Free PMC article. Review.
-
Safety and immunogenicity of inactivated poliovirus vaccine schedules for the post-eradication era: a randomised open-label, multicentre, phase 3, non-inferiority trial.Lancet Infect Dis. 2021 Apr;21(4):559-568. doi: 10.1016/S1473-3099(20)30555-7. Epub 2020 Oct 23. Lancet Infect Dis. 2021. PMID: 33284114 Free PMC article. Clinical Trial.
-
Immunogenicity of full and fractional dose of inactivated poliovirus vaccine for use in routine immunisation and outbreak response: an open-label, randomised controlled trial.Lancet. 2019 Jun 29;393(10191):2624-2634. doi: 10.1016/S0140-6736(19)30503-3. Epub 2019 May 16. Lancet. 2019. PMID: 31104832 Free PMC article. Clinical Trial.
-
Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study.Lancet Infect Dis. 2015 Nov;15(11):1273-82. doi: 10.1016/S1473-3099(15)00219-4. Epub 2015 Aug 26. Lancet Infect Dis. 2015. PMID: 26318714 Clinical Trial.
-
Immunogenicity of New Primary Immunization Schedules With Inactivated Poliovirus Vaccine and Bivalent Oral Polio Vaccine for the Polio Endgame: A Review.Clin Infect Dis. 2018 Oct 30;67(suppl_1):S35-S41. doi: 10.1093/cid/ciy633. Clin Infect Dis. 2018. PMID: 30376081 Free PMC article. Review.
Cited by
-
Inactivated Poliovirus Vaccine: Recent Developments and the Tortuous Path to Global Acceptance.Pathogens. 2024 Mar 4;13(3):224. doi: 10.3390/pathogens13030224. Pathogens. 2024. PMID: 38535567 Free PMC article. Review.
-
Persistence of immunity following a single dose of inactivated poliovirus vaccine: a phase 4, open label, non-randomised clinical trial.Lancet Microbe. 2023 Nov;4(11):e923-e930. doi: 10.1016/S2666-5247(23)00215-X. Epub 2023 Sep 26. Lancet Microbe. 2023. PMID: 37774729 Free PMC article. Clinical Trial.
References
-
- Centers for Disease Control and Prevention . Global immunization. Our progress against polio.2021. https://www.cdc.gov/polio/progress/index.htm. Accessed 20 July 2021.
-
- Rotary District 9820 . Polio endgame update.https://district9820.org/Stories/polio-endgame-update. Accessed 20 July 2021.
-
- Global Polio Eradication Initiative . Global eradication of wild poliovirus type 2 declared.https://polioeradication.org/news-post/global-eradication-of-wild-poliov.... Accessed 20 July 2021.
-
- Global Polio Eradication Initiative . Polio India polio fact sheet.https://polioeradication.org/wp-content/uploads/2016/07/PolioIndiaFactSh.... Accessed 20 July 2021.
-
- Global Commission for the Certification of the Eradication of Poliomyelitis . Meeting (1st: 1995: Geneva, Switzerland) and WHO Expanded Programme on Immunization. (1995). Report of the 1st Meeting of the Global Commission for the Certification of the Eradication of Poliomyelitis, Geneva, Switzerland, 16–17 February 1995. World Health Organization.https://apps.who.int/iris/handle/10665/59821. Accessed 2 August 2021.
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical